The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
This article was originally published on MedicalXpress.com
FDA approves SPEVIGO for generalized pustular psoriasis flares
You may also be interested in:
The Latest
Lyme carditis: Things can get complicated when Lyme disease affects heart function
Lyme disease is a tick-born infection caused by bacteria known as Borrelia burgdorferi. Lyme carditis is an early manifestation of Lyme disease that can occur two to six weeks after the tick bite. Approximately five to 10 per […]
The Latest
Colorful sweets may look tasty, but some researchers question whether synthetic dyes may pose health risks to your colon and rectum
Early-onset colorectal cancer incidence among the young, defined as those under age 50, has been rising globally since the early 1990s. Rates for colon and rectal cancers are expected to increase by 90% and 124%, respectively, by 2030. […]
The Latest
Canadians want home care, not long-term care facilities, after COVID-19
The COVID-19 pandemic has shed light on the precarious living conditions of the elderly in nursing homes in Canada. During the first wave of the pandemic, from March to August 2020, more than 80 per […]
Read More:
-
Researchers are joining forces with the food and health industries to tighten controls and improve nutrition for infants and children.This article was originally published on [...]
-
Toddlers whose moms were exposed to higher levels of air pollution during mid- to late-pregnancy tend to score lower on measures of cognition, motor coordination [...]
-
When visiting friends or family who have both houseplants and young children, I’ve been compared to “Aunt Bonnie” from the Geico commercial “Aunt Infestation.”This article [...]
